Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes
Posted: 31 May 2013 | | No comments yet
Novo Nordisk announced the submission to the EMA of the MAA for the approval of IDegLira…
![Novo Nordisk Logo](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Novo_Nordisk.gif)
![Novo Nordisk Logo](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Novo_Nordisk.gif)
Novo Nordisk today announced the submission to the European Medicines Agency of the marketing authorisation application for the approval of IDegLira, the combination product of insulin degludec (Tresiba®), the once-daily new-generation basal insulin analogue, with an ultra-long duration of action, and liraglutide (Victoza®), the once-daily human GLP-1 analogue. IDegLira has been developed for the treatment of people with type 2 diabetes.